Abstract
We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with rituximab, analyzing the quantitative alteration of target molecules, that is, CD20, CD22, CD55 and CD59, in Daudi and Raji cells as well as in cells obtained from patients with B-cell malignancies (BCM). Antibody inducing direct antiproliferative and apoptotic effect, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) were tested separately. In Daudi and Raji cells, the CDC effect of rituximab significantly increased within 12 h following incubation with CMC-544. The levels of CD22 and CD55 were significantly reduced (P<0.001 in both cells) after incubation with CMC-544, but CD20 level remained constant or increased for 12 h. Similar results were obtained in cells from 12 patients with BCM. The antiproliferative and apoptotic effect of CMC-544 were greater than that of rituximab. The ADCC of rituximab was not enhanced by CMC-544. Thus, the combination of CMC-544 and rituximab increased the in vitro cytotoxic effect in BCM cells, and sequential administration for 12 h proceeded by CMC-544 was more effective. The reduction of CD55 and the preservation of CD20 after incubation with CMC-544 support the rationale for the combined use of CMC-544 and rituximab.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fisher RL, Shah P . Current trends in large cell lymphoma. Leukemia 2003; 17: 1948–1960.
Fanale MA, Younes A . Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007; 67: 333–350.
Coiffier B . Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603–3613.
Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Giné E, Bosch F . How I treat refractory CLL. Blood 2006; 107: 1276–1283.
Smith MR . Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359–7368.
Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466–1471.
Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383–3389.
Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67: 10556–10563.
Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS et al. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood 2007; 110: 2049–2056.
DiJoseph JF, Amelino DC, Boghhaert ER, Khandke K, Dougher MM, Sridharan L et al. Antibody-targeted chemotherapy with CMC544: a CD22-tageted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103: 1807–1814.
Zein N, Sinha AM, McGahren WJ, Ellestad GA . Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988; 240: 1198–1201.
Fayad L, Patel H, Verhoef G, Cruczman M, Foran J, Gine E et al. Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study. Blood 2006; 108: 766a, absr. #2711.
DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006; 12: 242–249.
Sugimoto Y, Sato S, Tsukahara S, Suzuki M, Okochi E, Gottesman MM et al. Coexpression of a multidrug resistance gene (MDR1) and herpes simplex virus thymidine kinase gene in a bicistronic retroviral vector Ha-MDR-IRES-TK allows selective killing of MDR1-transduced human tumors transplanted in nude mice. Cancer Gene Ther 1997; 4: 51–58.
Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M et al. Reduced effect of gemtuzumab ozogamicin (CMC-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002; 16: 813–819.
Yasukawa M, Arai J, Kakimoto M, Sakai I, Kohno H, Fujita S . CD20-positive adult T-cell leukemia. Am J Hematol 2001; 66: 39–41.
Toba K, Hanawa H, Fuse I, Sakaue M, Watanabe K, Uesugi Y et al. Difference in CD22 molecules in human B cells and basophils. Exp Hematol 2002; 30: 205–211.
Hatanaka M, Seya T, Matsumoto M, Hara T, Nonaka T, Inoue N et al. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol- anchored complement regulatory proteins decayacceleratingfactor (CD55) and CD59 is lost in human leukaemia cell lines. Biochem J 1996; 314: 969–976.
Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shijo K et al. Caliceamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMC676) shows cytocydal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000; 14: 1436–1443.
Takeshita A, Shinjo K, Naito K, Matsui H, Sahara N, Shigono K et al. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005; 19: 1306–1311.
Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S . Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res 2006; 30: 625–631.
Karasawa S, Araki T, Yamamoto-Hino M, Miyawaki A . A green-emitting fluorescent protein from Galaxeidae coral and its monomeric version for use in fluorescent labeling. J Biol Chem 2003; 278: 34167–34171.
Cheson BD . Monoclonal antibody therapy for B-cell malignancies. Semin Oncol 2006; 33: S2–S14.
van der Kolk LE, Grillo-López AJ, Baars JW, van Oers MH . Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 2003; 17: 1658–1664.
Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F . Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35: 2175–2183.
Acknowledgements
We express our sincere gratitude to Wyeth Pharmaceuticals Inc. (USA) for their continuous support and for reviewing the article, and to Ms Yoshimi Suzuki, Ms Noriko Anma and Dr Kiyoshi Shibata (Equipment Center at Hamamatsu University School of Medicine) for technical assistance. This study was supported by Japanese grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology (19590552, 17590489).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takeshita, A., Yamakage, N., Shinjo, K. et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia 23, 1329–1336 (2009). https://doi.org/10.1038/leu.2009.77
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.77
Keywords
This article is cited by
-
Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies
Current Hematologic Malignancy Reports (2018)
-
Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia
International Journal of Hematology (2013)
-
Ongoing Development of Monoclonal Antibodies and Antibody Drug-Conjugates in Lymphoma
Current Oncology Reports (2011)